Discovery of a New Class of Potent, Selective, and Orally Bioavailable CRTH2 (DP2) Receptor Antagonists for the Treatment of Allergic Inflammatory Diseases
摘要:
A novel chemical class of potent chemoattractant receptor-homologous expressed on Th2 lymphocytes (CRTH2 or DP2) antagonists is reported. An initial and moderately potent spiro-indolinone compound (5) was found during a high-throughput screening campaign. Structure - activity relationship (SAR) investigation around the carboxylic acid group revealed that changes in this part of the molecule could lead to a reversal of functional activity, yielding weakly potent agonists. SAR investigation of the succinimide functional group led to the discovery of several single-digit nanomolar antagonists. The potency of these compounds was confirmed in a human eosinophil chemotaxis assay. Moreover, compounds (R)-58 and (R)-71 were shown to possess pharmacokinetic properties suitable for development as an orally bioavailable drug.
The present invention is related to the use of spiro derivatives of Formula (I) for the treatment and/or prevention of allergic diseases, inflammatory dermatoses and other diseases with an inflammatory component. Specifically, the present invention is related to the use of spiro derivatives for the modulation of CRTH2 activity.
[EN] TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS<br/>[FR] DERIVES SPIRO TRICYCLIQUES SERVANT DE MODULATEURS DE CRTH2
申请人:APPLIED RESEARCH SYSTEMS
公开号:WO2006125784A1
公开(公告)日:2006-11-30
[EN] The present invention is related to the use of spiro derivatives of Formula (I) for the treatment and/or prevention of allergic diseases, inflammatory dermatoses and other diseases with an inflammatory component. Specifically, the present invention is related to the use of spiro derivatives for the modulation of CRTH2 activity. [FR] L'invention concerne l'utilisation de dérivés spiro de formule (I) pour traiter et/ou pour prévenir des maladies allergiques, des dermatoses inflammatoires et d'autres maladies présentant une composante inflammatoire. En particulier, l'invention concerne l'utilisation de dérivés spiro pour moduler l'activité de CRTH2.